SELLAS Life Sciences Closes $172.5 Million Stock Offering
What happened
SELLAS Life Sciences Group, Inc. completed an underwritten public offering of 13,269,231 shares of common stock. The offering price was $13.00 per share, generating aggregate gross proceeds of $172.5 million before deducting expenses. Mizuho Securities and TD Cowen served as book-running managers for the offering, which was made under a shelf registration statement filed on March 20, 2026.
From manilatimes.net
Why it matters
The offering provides significant capital to SELLAS Life Sciences, a clinical biopharmaceutical company focused on developing therapies for cancer indications. The involvement of Mizuho Securities and TD Cowen as managers reflects activity within the investment banking sector.
From manilatimes.net
Who's involved
- Mizuho SecuritiesActed as a book-running manager for the offering.
- TD CowenActed as a lead book-running manager for the offering.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Mizuho SecuritiesSpeculative
Mizuho Securities could see direct revenue generation from acting as a book-running manager for the offering.
- TD CowenSpeculative
TD Cowen could see direct revenue generation from acting as a lead book-running manager for the offering.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Mizuho Securities
Japanese investment banking company
Nothing else this week.
-
TD Cowen
American investment bank